Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2002

View Archived Issues

FDA requests additional animal study before lifting Vasomax clinical hold

Drug pipeline for bipolar disorder

MLN-2704 enters phase I in androgen-independent prostate cancer

Elan completes sale of Abelcet to Enzon

FDA panel recommends approval of rhBMP for open long bone fractures

Positive opinion for Levitra in E.U.

New inhibitors of GSK-3 and/or ROCK kinase under study at Vertex

AstraZeneca presents novel cannabinoid CB2 agonists as potential analgesic agents

Japan Energy and Sumitomo describe new immunomodulators for cancer and other disorders

Novel Src kinase inhibitors in early development at AstraZeneca

Series of vascular damaging agents and their use in cancer, arthritis, diabetes, etc.

Bayer claims Raf kinase inhibitors with utility in cancer

Inhibitor of novel cancer target is selectively cytotoxic to tumor cells

Positive opinion issued in E.U. for Hepsera

PX-478, the lead in a novel class of HIF-1 inhibitors with excellent antitumor activity

Antiangiogenic/antimetastatic peptide completes preclinical evaluation

Ethypharm and Conba enter into strategic alliance

NeuroSearch and GlaxoSmithKline target depression

Probiodrug and Synt:em to apply Pep:trans technology for the treatment of CNS diseases

Additional primary endpoint data released from phase III Aldurazyme study

New Backgrounder published -- Rhinovirus posted November 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...